Cholecystokinin receptor Inhibitors
2 drugsAbout Cholecystokinin receptor
The Cholecystokinin receptor (CCK receptor) is a G protein-coupled receptor that binds cholecystokinin, a peptide hormone involved in various physiological processes like digestion. It regulates digestive functions and potentially other functions through downstream signaling pathways.
Currently, there is no genetic evidence directly linking the CCK receptor to specific diseases. Despite the lack of genetic validation, it remains a drug development target due to its role in regulating digestion.
Two FDA-approved drugs, KINEVAC and SINCALIDE, target the CCK receptor, both are small molecules. These drugs are marketed by BRACCO and MAIA PHARMS INC, respectively, for therapeutic areas outside major indications.
Top Cholecystokinin receptor Drugs
The competitive landscape consists of two companies, BRACCO and MAIA PHARMS INC.
Low market concentration suggests relatively low barriers to entry for new competitors.
Cholecystokinin receptor Drug Modality Landscape
Modalities
Routes of Administration
Cholecystokinin receptor is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like peptides or antibodies could create differentiation opportunities.
Cholecystokinin receptor Clinical Trials 3 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cholecystokinin receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Cholecystokinin receptor Drug Approval Timeline (1976 - 2022)
The first drug was approved in 1976, and the most recent in 2022, spanning 47 years.
The long approval span indicates sustained interest, but recent approval suggests renewed potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cholecystokinin receptor. A trial counts if an approved drug acting on Cholecystokinin receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.